TY - JOUR
T1 - Incidence of Parkinson’s disease in French women from the E3N cohort study over 27 years of follow-up
AU - Canonico, Marianne
AU - Artaud, Fanny
AU - Degaey, Isabelle
AU - Moisan, Frédéric
AU - Kabore, Rahime
AU - Portugal, Berta
AU - Nguyen, Thi Thu Ha
AU - Pesce, Giancarlo
AU - Boutron-Ruault, Marie Christine
AU - Roze, Emmanuel
AU - Elbaz, Alexis
N1 - Funding Information:
This work was realized with the data of the E3N cohort (Inserm) and supported by the Mutuelle Générale de l’Education Nationale (MGEN), the Gustave Roussy Institute, and the French League against Cancer for the constitution and maintenance of the cohort. This work has benefited from State aid managed by the National Research Agency (ANR) under the program “Investment in the future” bearing the reference ANR-10-COHO-0006 and under the program “Young researcher” bearing the reference ANR-18-CE36-0006–01 as well as a subsidy from the Ministry of Higher Education, Research and Innovation for public service charges bearing the reference N°2102918823, 2103236497, and 2103586016.
Funding Information:
BP is funded by a doctoral grant from the French Ministry of research. TTHN is funded by a Michael J Fox foundation post-doctoral grant. GP is funded by an ANR post-doctoral grant. MCBR received speaker fees in 2020 from MAYOLI-SPINDLER and GILEAD outside the field of the present paper. ER received honorarium for speech from Orkyn Aguettant, Elivie and for participating in an advisory board from Allergan. He received research support from Merz-Pharma, Orkyn, Aguettant, Elivie, Ipsen, Allergan, Everpharma, Fondation Desmarest, AMADYS, ADCY5.org, Agence Nationale de la Recherche, Societé Française de Médecine Esthétique, and Dystonia Medical Reasearch Foundation. AE has obtained research grants from the Michael J Fox foundation, Plan Ecophyto (French ministry of agriculture), and France Parkinson.
Publisher Copyright:
© 2022, Springer Nature B.V.
PY - 2022/5
Y1 - 2022/5
N2 - Parkinson’s disease (PD) is an uncommon disease with a long prodromal period and higher incidence in men than women. Large cohort studies of women with a long follow-up are needed. Within the E3N French cohort study (98,995 women, 40–65 years at baseline), we identified 3,584 participants who self-reported PD or used anti-parkinsonian drugs over 27 years (1992–2018). We obtained medical records to validate PD diagnosis (definite, probable, possible, no). When medical records were not available, we used a validated algorithm based on drug claims to predict PD status. We retained a PD diagnosis for 1,294 women (medical records, 62%; algorithm, 38%). After exclusion of prevalent/possible cases, cases without age at diagnosis, and women lost to follow-up, our analyses included 98,069 women, of whom 1,200 had incident PD (mean age at diagnosis = 71.8 years; incidence rate = 0.494/1,000 person-years). Age-adjusted incidence rates increased over the six first years of follow-up, possibly due to healthy volunteer bias, and remained stable thereafter, similar to incidence rates in women from Western Europe. Forty three percent of PD cases occurred after 20 years of follow-up (2012–2018). The cumulative incidence of PD from 50 to 90 years was 2.41% (95% confidence interval [CI] = 2.27–2.65). PD incidence was lower in ever than never smokers (hazard ratio = 0.86, 95% CI = 0.76–0.96). In conclusion, we estimated PD incidence rates in French women over a 27-year follow-up, and showed stable incidence between 2002 and 2018. The long follow-up and large sample size make this study a valuable resource to improve our knowledge on PD etiology in women.
AB - Parkinson’s disease (PD) is an uncommon disease with a long prodromal period and higher incidence in men than women. Large cohort studies of women with a long follow-up are needed. Within the E3N French cohort study (98,995 women, 40–65 years at baseline), we identified 3,584 participants who self-reported PD or used anti-parkinsonian drugs over 27 years (1992–2018). We obtained medical records to validate PD diagnosis (definite, probable, possible, no). When medical records were not available, we used a validated algorithm based on drug claims to predict PD status. We retained a PD diagnosis for 1,294 women (medical records, 62%; algorithm, 38%). After exclusion of prevalent/possible cases, cases without age at diagnosis, and women lost to follow-up, our analyses included 98,069 women, of whom 1,200 had incident PD (mean age at diagnosis = 71.8 years; incidence rate = 0.494/1,000 person-years). Age-adjusted incidence rates increased over the six first years of follow-up, possibly due to healthy volunteer bias, and remained stable thereafter, similar to incidence rates in women from Western Europe. Forty three percent of PD cases occurred after 20 years of follow-up (2012–2018). The cumulative incidence of PD from 50 to 90 years was 2.41% (95% confidence interval [CI] = 2.27–2.65). PD incidence was lower in ever than never smokers (hazard ratio = 0.86, 95% CI = 0.76–0.96). In conclusion, we estimated PD incidence rates in French women over a 27-year follow-up, and showed stable incidence between 2002 and 2018. The long follow-up and large sample size make this study a valuable resource to improve our knowledge on PD etiology in women.
KW - Cohort
KW - Drug claims
KW - Incidence
KW - Medical records
KW - Parkinson’s disease
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=85126176496&partnerID=8YFLogxK
U2 - 10.1007/s10654-022-00851-y
DO - 10.1007/s10654-022-00851-y
M3 - Article
C2 - 35286513
AN - SCOPUS:85126176496
SN - 0393-2990
VL - 37
SP - 513
EP - 523
JO - European Journal of Epidemiology
JF - European Journal of Epidemiology
IS - 5
ER -